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Camptotheca Decaisne is a genus of the family Nys-
saceae native to China. It is the major natural source of 
camptothecins (CPTs), anti-cancer alkaloids. CPTs (Fig. 1) 
have shown promising anti-cancer activity in almost all 
kinds of cancer in clinical trials in the USA, China, Japan, 
and Europe since 1957, and especially those since 1986 [1]. 
The CPT agents have also shown potent anti-viral activity 
against HIV in both animal and human cell cultures [2]. In 
1996, Topotecan (TPT, Hycamtin) and Irinotecan (CPT-11, 
Camptosar), two semi-synthetic CPT drugs were approved 
by the FDA for the treatment of patients with advanced  
ovarian and colon cancer, respectively. In 1998, Topotecan 
was approved by the FDA for treatment of small cell  
lung cancer. 9-Nitrocamptothecin (9-NC, Rubitecan), 9-
Aminocamptothecin (9-AC) and several other CPT analogs 
(e.g., CZ112) also show promising results in clinical trials. 
In fact, CPT agents have been recognized as the most prom-
ising anti-cancer drugs in the world. Therefore, worldwide 
demand for CPTs is dramatically increasing. Currently, CPT 
production is still dependent on natural supply. However, 
Camptotheca trees grow rapidly, and many parts of the tree 
can be used to extract drug CPTs.  
The earliest record of the Camptotheca tree dated back to 
1848 in the Chinese book, Zhi Wu Ming Shi Tu Kao [1]. Un-
til 1965, when CPT was first isolated from Camptotheca [3], 
only 25 publications were available worldwide on Camp-
totheca; and all of these to treating only botanical aspects 
[1]. By February 2000, 540 patents had been granted world-
wide and approximately1,500 journal articles had been pub-
lished. Over 95% of the publications, however, dealt with 
either chemical or medical aspects of CPTs with only about 
5% focusing on the Camptotheca tree, itself. Principal re-
search studies on Camptotheca taxonomy [4-6], anatomy and 
morphology [1, 7-10], phylogeny [11-13], embryology [14], 
chromosome numbers [15], pollination biology [14, 16, 17], 
geography [1, 18, 19], and physiology [20-22].  
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Fig. (1). Chemical structure of camptothecin (CPT) and its main 
derivatives as anti-cancer drugs in clinical treatments and trials. 
 
Obviously, a systematic study of Camptotheca as phar-
maceutical crops for production of CPTs is needed. Theo-
retically, taxonomic and genetic diversity, and CPT produc-
tion ecology are still poorly understood. Our studies have 
identified at least three problems with the development of 
Camptotheca as a source for CPTs. First, Camptotheca is an 
endangered genus whose wild populations may possibly be 
nearing extinction. Second, the gene pool of Camptotheca in 
the USA is extremely small. Most of the trees in the USA are 
traceable to only two mature trees in Chico, California, that 
germinated from seeds imported from southern China in 
1934. Selfing is often the only natural breeding system for 
the Camptotheca trees in USA; and these offsprings are 
normally of low quality. In addition, asexual propagation is 
the method commonly used to reproduce Camptotheca seed-
lings in the USA. Third, cold-hardiness and drought-
tolerance are two major problems in the development of 
plantations in the southeastern USA. The present genetic 
resource base of Camptotheca in the USA is too small to 
select for either cold-hardiness, drought-tolerance, or high-
CPT-yielding genotypes. 
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Fig. (2). Strategies to develop Camptotheca as pharmaceutical crops at the National Center for Pharmaceutical Crops, Arthur Temple College 
of Forestry and Agriculture, Stephen F. Austin State University, Nacogdoches, Texas, USA. 
 
To solve the above problems, researchers at National 
Center for Pharmaceutical Crops, Arthur Temple College of 
Forestry and Agriculture, Stephen F. Austin State University 
began our Camptotheca research project in the early 1990s. 
The financial support has been received from the Houston 
Livestock Show and Rodeo, the Fondren Foundation, Ste-
phen F. Austin State University, Chinese Ministry of For-
estry, David Dolben, Jack Hicks, and Charles Poland. To 
develop Camptotheca as pharmaceutical crops, the studies 
have been conducted in four aspects from 1993 to 2010  
(Fig. 2):  
1. Evaluation of the potential of CPTs as anti-cancer and 
anti-viral drugs [1] (1993-1994).  
2. Investigation of the Camptotheca resource worldwide, 
including distribution (identification of its endangered 
status), phenotypic variations, micromorphological 
analysis, taxonomic treatment (the discovery and descrip-
tion of new species) [6], and ethnobotanical survey 
(1994-1997).  
3. Development of strategies to maximize CPTs production 
in Camptotheca, including the establishment of an exclu-
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sive germplasm preserve, the detection of genetic diver-
sity with DNA RAPD markers, the development of a 
high-CPT-yielding cultivar [23], the discovery of CPT 
accumulation sites in trees [24], strategy development for 
induced production of CPT in plants [25], discovery of 
induced endogenous autotoxicity (abnormal morpho-
genesis) following decapitation pruning [26], and the im-
provement of CPT extraction methods (1993-2010). 
4. Identification of new bioactive compounds and products, 
including isolation of new anti-tumor CPT analogs [27], 
identification of new antifungal compounds [28, 29], de-
velopment of termite control products [30] (1997-2010).  
This special issue primarily includes unpublished re-
search data in taxonomy, phenotypic and micromorphologi-
cal variations, anatomy, genetic variations, distribution, eth-
nobotany, cultivar development, and trichome management 
and overview of chemical composition at National Center for 
Pharmaceutical Crops, Arthur Temple College of Forestry 
and Agriculture, Stephen F. Austin State University. These 
articles may provide useful data fundamental to the conser-
vation of the species as well as various strategies to develop 
and manage Camptotheca as pharmaceutical crops. This spe-
cial issue will also include research report on other plant 
sources of CPTs at the University of Puerto Rico.  
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